TARS Logo

Tarsus Pharmaceuticals, Inc. (TARS) 

NASDAQ
Market Cap
$1.8B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
303 of 776
Rank in Industry
177 of 433

Largest Insider Buys in Sector

TARS Stock Price History Chart

TARS Stock Performance

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops …

Insider Activity of Tarsus Pharmaceuticals, Inc.

Over the last 12 months, insiders at Tarsus Pharmaceuticals, Inc. have bought $18,960 and sold $3.52M worth of Tarsus Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Tarsus Pharmaceuticals, Inc. have bought $8.14M and sold $15.77M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Goldberg Andrew D. (director) — $18,960.

The last purchase of 1,000 shares for transaction amount of $18,960 was made by Goldberg Andrew D. (director) on 2023‑12‑15.

List of Insider Buy and Sell Transactions, Tarsus Pharmaceuticals, Inc.

2024-08-12Saledirector
35,000
0.0914%
$26.08$912,961+24.57%
2024-06-18SaleSee Remarks
10,445
0.0233%
$27.47$286,924+6.42%
2024-03-18SaleChief Operating Officer
4,879
0.013%
$30.60$149,297+7.84%
2024-03-18SaleChief Commercial Officer
4,766
0.0127%
$30.60$145,840+7.84%
2024-03-18SaleGeneral Counsel
4,436
0.0118%
$30.60$135,742+7.84%
2024-03-18SaleChief Human Resources Officer
4,314
0.0115%
$30.60$132,008+7.84%
2024-03-18SalePresident/CEO and Board Chair
10,415
0.0278%
$30.60$318,699+7.84%
2023-12-27SalePresident/CEO and Board Chair
8,000
0.024%
$20.22$161,760+58.41%
2023-12-20SalePresident/CEO and Board Chair
40,000
0.1223%
$20.27$810,623+59.54%
2023-12-20SaleCHIEF MEDICAL OFFICER
2,252
0.0068%
$20.00$45,040+59.54%
2023-12-15Purchasedirector
1,000
0.003%
$18.96$18,960+67.35%
2023-11-30SaleGeneral Counsel
8,356
0.025%
$16.31$136,286+91.65%
2023-11-30SaleChief Human Resources Officer
8,355
0.025%
$16.31$136,270+91.65%
2023-11-15SalePresident/CEO and Board Chair
8,000
0.0252%
$18.37$146,933+73.92%
2023-10-18SalePresident/CEO and Board Chair
8,000
0.0245%
$13.24$105,920+125.00%
2023-10-05SaleCHIEF MEDICAL OFFICER
1,604
0.0051%
$18.00$28,872+52.54%
2023-09-20SalePresident/CEO and Board Chair
8,000
0.0252%
$17.21$137,680+62.69%
2023-08-23SalePresident/CEO and Board Chair
8,000
0.0244%
$17.23$137,840+48.79%
2023-08-15Purchasedirector
9,506
0.035%
$16.80$159,701+48.59%
2023-07-19SalePresident/CEO and Board Chair
103,900
0.3866%
$20.01$2.08M+13.60%

Insider Historical Profitability

28.73%
Goldberg Andrew D.director
3000
0.0079%
$47.3410
Vivo Capital IX, LLC10 percent owner
2469001
6.4902%
$47.34110+36.85%
Tester Jason E.
1920933
5.0495%
$47.3410+36.85%
Horowitz Limited Partnership VIII10 percent owner
1920933
5.0495%
$47.3410+36.85%
Frazier Life Sciences IX, L.P.10 percent owner
1917157
5.0396%
$47.3410+36.85%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RTW Investments, LP$118.95M8.663.27M+3.81%+$4.36M1.78
Paradigm BioCapital Advisors LP$104.08M7.582.86M+179.36%+$66.83M3.78
BlackRock$96.42M7.022.65M+5.43%+$4.96M<0.01
Morgan Stanley$87.2M6.352.4M+22.54%+$16.04M0.01
Tang Capital Management, LLC$81.96M5.972.25M+2.27%+$1.82M0.31
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.